Peak Bio (PKBO) Stock Price, News & Analysis

Company Overview

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.11
• 52-Week Range: $0.00 to $0.26
• Volume: 66,140 shs
• Average Volume: 8,940 shs
• Market Capitalization: $520.31 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PKBO Stock Analysis - Frequently Asked Questions

How were Peak Bio's earnings last quarter?

Peak Bio, Inc. (NASDAQ:PKBO) posted its quarterly earnings results on Tuesday, November, 12th. The company reported $0.06 earnings per share for the quarter.

What other stocks do shareholders of Peak Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Peak Bio investors own include Check-Cap (CHEK), Pulmonx (LUNG), Minerva Neurosciences (NERV), Crescent Biopharma (CBIO), Adicet Bio (ACET), Absci (ABSI) and Aeglea BioTherapeutics (AGLE).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 7/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PKBO
• CIK: 1834645
• Web: peak-bio.com
• Phone: 650-549-9103
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.83 million
• Net Margins: N/A
• Pretax Margin: -4,433.33%
• Return on Equity: N/A
• Return on Assets: -179.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $370 thousand
• Price / Sales: 1.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.90) per share
• Price / Book: -0.03

Miscellaneous

• Outstanding Shares: 23,125,000
• Free Float: 18,523,000
• Market Cap: $520.31 thousand
• Optionable: Not Optionable
• Beta: 1.75